(primary solid tumor cohort)
This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.
Testing the association between 'NFE2L2 MUTATION ANALYSIS' and 4 clinical features across 12 patients, no significant finding detected with Q value < 0.25.
-
No gene mutations related to clinical features.
Clinical Features |
Time to Death |
AGE | NUMBERPACKYEARSSMOKED | TOBACCOSMOKINGHISTORYINDICATOR | ||
nMutated (%) | nWild-Type | logrank test | t-test | t-test | t-test | |
NFE2L2 | 3 (25%) | 9 |
0.317 (0.952) |
0.391 (0.952) |
0.479 (0.952) |
-
Mutation data file = CESC-TP.mutsig.cluster.txt
-
Clinical data file = CESC-TP.clin.merged.picked.txt
-
Number of patients = 12
-
Number of significantly mutated genes = 1: 'NFE2L2 MUTATION ANALYSIS'
-
Number of selected clinical features = 4
-
Exclude genes that fewer than K tumors have mutations, K = 3
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.